Bliuc, D <br/><br/>
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.  [electronic resource] 

 -  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA  Apr 2019 
 - 817-828 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Observational Study 
<br/><br/><label>ISSN: </label>1433-2965 
<br/><br/><label>Standard No.: </label>10.1007/s00198-018-4806-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Alendronate--therapeutic use<br/>Bone Density Conservation Agents--therapeutic use<br/>Canada--epidemiology<br/>Diphosphonates--therapeutic use<br/>Etidronic Acid--therapeutic use<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Osteoporosis--drug therapy<br/>Osteoporotic Fractures--mortality<br/>Prospective Studies<br/>Risedronic Acid--therapeutic use<br/>Risk Factors<br/>Risk Reduction Behavior